Oronazol (Ketoconazole)

Ketoconazole, the active ingredient in Oronazol, is an antifungal presented as an oral dosage form for systemic use. It treats fungal infections of the skin, nails and mucous membranes in adult patients. GNH USA supplies Oronazol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Ketoconazole is an azole antifungal that targets fungal infections of the skin and mucous membranes. - Dermatophyte infections: reduces fungal growth on skin and nails, improving lesions. - Seborrheic dermatitis: alleviates scaling, redness and itching of affected areas. - Pityriasis versicolor: clears pigmentary changes caused by Malassezia species. - Candidiasis: treats oral and esophageal candidiasis, relieving discomfort and infection.

Ketoconazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: occasional stomach upset after oral intake. - Abdominal pain: mild discomfort in the gastrointestinal tract. - Headache: transient cranial pain. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Adrenal insufficiency: suppression of steroid synthesis with prolonged use.

Ketoconazole should be used with careful clinical oversight. - Liver function monitoring: assess baseline and periodic liver enzymes. - Drug interactions: review concomitant medications, especially CYP3A4 substrates and inhibitors. - Pregnancy: avoid unless benefits outweigh potential fetal risk. - Breastfeeding: contraindicated due to excretion in milk. - Renal impairment: use with caution and adjust if necessary. - Store at ambient temperature: keep in original container, protect from moisture.

Ketoconazole can alter the plasma levels of several co‑administered drugs.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase ketoconazole concentrations and toxicity. - CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce antifungal efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: ketoconazole may potentiate anticoagulant effect, requiring INR monitoring. - Statins: increased risk of myopathy when combined with certain statins. - Oral contraceptives: reduced hormonal effectiveness, consider alternative contraception.